Patent intelligence · US
US 11198858
Codon optimized GLA genes and uses thereof
Codon optimized GLA genes and uses thereof
Patent details — US 11198858
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 14, 2021
- Expiration
- Dec 9, 2041
- Applicant
- 4D MOLECULAR THERAPEUTICS INC.
- Claims
- 23
- CPC classes
- A61K, A61K48/00, A61K48/005, A61K48/0066
Quick answer
US 11198858 (Codon optimized GLA genes and uses thereof) is held by 4D MOLECULAR THERAPEUTICS INC.. Status: granted. Granted Dec 14, 2021. Expires Dec 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- 4D MOLECULAR THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K48/00, A61K48/005, A61K48/0066, A61K48/0075, A61K48/0083
More from 4D MOLECULAR THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 11840704
Adeno-associated virus variant capsids and methods of use thereof
granted -
US 11807868
Adeno-associated variants, formulations and methods for pulmonary delivery
granted -
US 11766489
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
granted -
US 11766487
Treatments for retinal disease
granted -
US 11576983
Treatments for retinal disease
granted -
US 11524081
Codon optimized REP1 genes and uses thereof
granted -
US 11499166
Adeno-associated variants, formulations and methods for pulmonary delivery
granted -
US 11419949
Adeno-associated virus variant capsids and methods of use thereof
granted
Frequently asked questions
What is US patent 11198858?
US 11198858 (Codon optimized GLA genes and uses thereof) is held by 4D MOLECULAR THERAPEUTICS INC.. Status: granted. Granted Dec 14, 2021. Expires Dec 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11198858?
4D MOLECULAR THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 11198858 expire?
Our index shows an expiration date of Dec 9, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.